There are, of course, many different pharmaceuticals available, depending on the condition. Sometimes it's the difference between a generic and a brand-name medicine. I think it's the intention of the panel to move the generic medicines into a public system, and perhaps not retain exclusivity but that you would offer a degree of patient choice around some of these brand names through private insurance.
On December 6th, 2016. See this statement in context.